Delveinsight

FEBRUARY 16, 2021

Numerous immunotherapy-based combinations are already trying in the old game of gleek to stake up some share in previously untreated, metastatic kidney cancer; however, the market seems to expand as the new entrants continue to make their entry. Padcev is a first-in-class antibody-drug conjugate (ADC) directed against Nectin-4, a protein.

Marketing 52

Marketing Protein Bioavailability Drugs 52

The Pharma Data

DECEMBER 9, 2020

Atlas cofounded, seeded and incubated Vigil, with pre-clinical stage assets in-licensed from Amgen Inc., The company plans to do this by developing drugs that eliminate protein aggregation by either reducing the production of toxic proteins or removing them after the fact through autophagy. which will remain a key shareholder.

Marketing 52

Marketing In-Vivo Protein In-Vitro 52

Delveinsight

JANUARY 7, 2021

The immunotherapy pipeline is led by an in-licensed EP4 antagonist that Ikena is testing combined with Keytruda in phase 1b/2 colorectal and non-small cell lung cancer clinical trials. The startup recently raised USD 87 million to propel itself in a competitive market. Ikena will back a pipeline that falls into two categories.

RNA 52

RNA Clinical Trials Clinical Trials Trials 52

The Pharma Data

NOVEMBER 11, 2020

As an orally bioavailable small molecule with broad antiviral activity, SLV213 could be a valuable treatment to meet today’s urgent need to fight COVID-19 as well other life-threatening infectious diseases, such as Chagas disease, Ebola virus disease, and Nipah virus infection.”. “As About Selva Therapeutics.

Protein 52

Protein Bioavailability Development Drugs 52